Patents by Inventor Emanuela Lovati

Emanuela Lovati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors
    Publication number: 20240000791
    Abstract: The present invention relates to compositions and methods for treating patients with cancer having a RET gene abnormality comprising administering HM06/TAS0953, for example patients with non-small cell lung cancer (NSCLC), and that may also have brain and/or leptomeningeal metastases, or another solid tumor; where the patient is administered an effective amount of HM06/TAS0953, where the HM06/TAS0953 can be formulated in a composition and administered orally in a single or multiple doses; and where the patients may have previously received and/or have developed resistance to another RET-selective or multi-kinase inhibitor.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 4, 2024
    Applicants: Helsinn Healthcare SA, Taiho Pharmaceutical Co., Ltd.
    Inventors: Emanuela Lovati, Ruben Giorgino, Simona Doria, Claudio Giuliano, Annalisa Bonifacio, Miharu Igarashi, Isao Miyazaki, Masanori Kato, Alberto Bernareggi
  • SUBSTITUTED 4-PHENYL-PYRIDINES
    Publication number: 20220401463
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: March 21, 2022
    Publication date: December 22, 2022
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Fosnetupitant chloride hydrochloride having improved stability
    Patent number: 11312698
    Abstract: Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • SUBSTITUTED 4-PHENYL-PYRIDINES
    Publication number: 20200399240
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 24, 2020
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Substituted piperaziniums for the treatment of emesis
    Patent number: 10717721
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 21, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • SOLUTION COMPRISING THE CHLORIDE HYDROCHLORIDE SALT OF 4-(5-(2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-N,2-DIMETHYLPROPANAMIDO)-4-(o-TOLYL)PYRIDIN-2-YL)-1-METHYL-1-((PHOSPHONOOXY)METHYL)PIPERAZIN-1-IUM (FOSNETUPITANT) AND PALONOSETRON HYDROCHLORIDE IN COMBINATION WITH DEXAMETHASONE AS A NEUROKININ RECEPTOR MODULATOR
    Publication number: 20190177296
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
    Patent number: 10208073
    Abstract: Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 19, 2019
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • SUBSTITUTED 4-PHENYL-PYRIDINES
    Publication number: 20180194788
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 12, 2018
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Therapeutic Uses of Elsiglutide
    Publication number: 20180177849
    Abstract: The invention relates to therapeutic uses of elsiglutide, particularly for protecting and stimulating bone marrow and peripheral blood cell type activity or immune-response in patients compromised due to the administration of chemotherapeutic agents. The invention further provides uses of elsiglutide to enhance the antitumor activity of cytotoxic chemotherapeutic agents and target specific biological agents.
    Type: Application
    Filed: October 6, 2017
    Publication date: June 28, 2018
    Inventors: Claudio Pietra, Emanuela Lovati, Youcef M. Rustum
  • Substituted piperaziniums for the treatment of emesis
    Patent number: 9908907
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 6, 2018
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • Therapeutic Uses of Elsiglutide
    Publication number: 20170087216
    Abstract: The invention relates to therapeutic uses of elsiglutide, particularly for protecting and stimulating bone marrow and peripheral blood cell type activity or immune-response in patients compromised due to the administration of chemotherapeutic agents. The invention further provides uses of elsiglutide to enhance the antitumor activity of cytotoxic chemotherapeutic agents and target specific biological agents.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 30, 2017
    Inventors: Claudio Pietra, Emanuela Lovati, Youcef M. Rustum
  • Substituted 4-Phenyl Pyridines
    Publication number: 20170050993
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 23, 2017
    Applicant: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
    Patent number: 9403772
    Abstract: Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 2, 2016
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • SUBSTITUTED 4-PHENYL-PYRIDINES
    Publication number: 20150011510
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: November 28, 2012
    Publication date: January 8, 2015
    Applicant: HELSINN HEALTHCARE SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Guiliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Methods of treating emesis
    Patent number: 8895586
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: November 25, 2014
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES
    Publication number: 20130231315
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: April 17, 2013
    Publication date: September 5, 2013
    Applicant: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stell
  • Substituted 4-phenyl pyridines having anti-emetic effect
    Patent number: 8426450
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: April 23, 2013
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella